IL2 and acute coronary syndrome: The ongoing LILACS and IVORY clinical trials, conducted by Zhaoet al. [25] and Sriranjan et al. [26], advocate the expansionof Tregs using low-dose IL-2 for the treatment of stable ischemic heart diseaseand acute coronary syndrome.